Evaluation and Management of Elevated TSH with Elevated T3

Pathophysiology

• In a normal feedback loop, high circulating T3/T4 suppresses TSH to undetectable levels (< 0.01 mU/L); therefore a combination of elevated TSH and elevated T3 is physiologically contradictory. 1

Key Differential Diagnoses

TSH‑Producing Pituitary Adenoma

• TSH‑producing adenomas represent roughly 1 % of all pituitary tumors (43 of 4 400 cases in multicenter series). 2
• Most patients present with a diffuse goiter and clinical signs of thyrotoxicosis. 2
• Approximately 40 % develop visual‑field deficits due to mass effect. 2
• About 25 % co‑secrete prolactin or growth hormone. 2
• Pituitary MRI usually shows a lesion larger than 1 cm, often with suprasellar extension. 2
• A disproportionately high pituitary glycoprotein α‑subunit (α‑subunit/TSH > 1) is a biochemical marker of adenoma. 2
• The TSH response to TRH is blunted in this condition. 2

Thyroid Hormone Resistance (RTH)

• RTH should be considered when there is a positive family history and no pituitary mass on imaging. 3
• The biochemical pattern mirrors that of a TSH‑producing adenoma: normal or elevated TSH together with elevated T3/T4. 3
• Genetic testing frequently identifies mutations in the thyroid‑hormone‑receptor β (TRβ) gene. 3
• Patients often have milder clinical symptoms than expected for the hormone levels, and TSH remains unsuppressed. 3

Diagnostic Algorithm

Step 1 – Biochemical Confirmation

• Repeat fasting measurements of TSH, free T4, and total or free T3 to verify the persistent pattern of elevated TSH (≥ 0.3 mU/L) with elevated T3. 1

Step 2 – Exclude Assay Interference

• Consider heterophile antibodies as a cause of spuriously high TSH; repeat the assay using an alternative method if clinical‑laboratory discordance exists. 3

Step 3 – Pituitary Imaging

• Perform contrast‑enhanced pituitary MRI; this study is mandatory for all patients with the abnormal hormonal pattern. 2

Step 4 – Additional Hormonal Tests

• Measure pituitary α‑subunit, prolactin, and growth‑hormone levels; an α‑subunit/TSH ratio > 1 supports a TSH‑producing adenoma.
• Assess sex‑hormone‑binding globulin (SHBG); it is elevated in true thyrotoxicosis. 2

Step 5 – Genetic and Family Evaluation

• Obtain a detailed family history of thyroid disorders.
• If MRI is normal, conduct genetic testing for TRβ mutations to confirm RTH. 3
• Offer thyroid‑function testing to first‑degree relatives when RTH is suspected. 3

Management Strategies

TSH‑Producing Adenoma

• First‑line therapy: trans‑sphenoidal surgical resection. 2
• Pre‑operative normalization of thyroid status with antithyroid drugs (methimazole or propylthiouracil) is recommended. 2
• Long‑term antithyroid medication is not advised as definitive therapy. 2
• Pre‑operative somatostatin analogues may shrink the tumor and lower TSH secretion. 2
• Pituitary radiotherapy is an alternative when surgery is contraindicated or incomplete. 2

Thyroid Hormone Resistance

• Antithyroid drugs or thyroid ablation are contraindicated; patients require relatively high thyroid‑hormone levels for normal tissue function. 3
• Symptomatic treatment is directed at tissue‑specific excess hormone effects (e.g., beta‑blockers for tachycardia). 3
• Genetic counseling and cascade testing of family members are advised. 3

Common Pitfalls to Avoid

• Do not assume primary hyperthyroidism without confirming TSH; the elevated‑TSH/ elevated‑T3 pattern is physiologically impossible in primary disease. 3
• Radioactive iodine uptake scanning is not indicated for central hyperthyroidism (TSH‑producing adenoma or RTH). 3
• Initiating radioactive iodine therapy or thyroidectomy without a definitive diagnosis can worsen outcomes in RTH. 3
• Factitious thyrotoxicosis from exogenous thyroid hormone typically suppresses TSH, not elevates it. 2
• Early‑pregnancy hCG suppresses TSH; it does not cause an elevated‑TSH/ elevated‑T3 profile. 1

Diagnostic Differentiation of Thyroid Hormone Resistance

Pituitary Imaging and α‑Subunit Assessment

• Obtain a pituitary MRI and measure the α‑subunit/TSH ratio; an elevated α‑subunit together with a visible pituitary mass confirms a TSH‑secreting adenoma, which requires surgical resection rather than symptomatic management of resistance to thyroid hormone. American College of Endocrinology & American Association of Clinical Endocrinologists – evidence level not specified. 4

Genetic Testing for TRβ Mutations

• Perform genetic testing for thyroid‑hormone‑receptor‑β (TRβ) mutations when MRI is normal and a family history suggests resistance to thyroid hormone; a positive result confirms the diagnosis and prevents inappropriate thyroid ablation. American College of Endocrinology & American Association of Clinical Endocrinologists – evidence level not specified. 4

Clinical Features Distinguishing RTH from TSH‑Secreting Adenoma

• Assess clinical characteristics: patients with resistance to thyroid hormone typically exhibit milder symptoms than expected for their hormone levels, lack visual‑field deficits, have normal sex‑hormone‑binding globulin, and show a preserved (not blunted) TSH response to TRH. These findings help differentiate RTH from a TSH‑secreting pituitary adenoma. American College of Endocrinology & American Association of Clinical Endocrinologists – evidence level not specified. 4